New perspectives on CKD-induced dyslipidemia by Bermúdez López, Marcelino et al.
  
 
 
Document downloaded from:  
http://hdl.handle.net/10459.1/63143 
 
 
 
The final publication is available at:  
https://doi.org/10.1080/14728222.2017.1369961 
 
 
 
Copyright  
(c) Taylor & Francis, 2017 
 
1 
 
New perspectives on CKD-induced dyslipidemia  
 
 
Marcelino Bermúdez-López1*, David Arroyo1, Àngels Betriu1, Luis Masana2, Elvira 
Fernández1, Jose M Valdivielso1* 
 
1 Vascular and Renal Translational Research Group; Institute for Biomedical Research of Lleida 
(IRBLleida); REDinREN del ISCIII, Lleida, Spain 
2 Unitat de Medicina Vascular i Metabolisme, Sant Joan University Hospital, IISPV, CIBERDEM, 
Universitat Rovira I Virgili, Reus, Spain 
* Corresponding authors: 
Marcelino Bermúdez-López MD. PhD. E-mail: mbermudez@irblleida.cat 
José Manuel Valdivielso, PhD. E-mail: valdivielso@medicina.udl.es 
 
 
 
 
 
Key Words: atherosclerosis, cardiovascular disease, chronic kidney disease, 
dyslipidemia, lipoproteins. 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
Introduction: chronic kidney disease (CKD) is a world-wide health concern associated 
with a significantly higher cardiovascular morbidity and mortality. One of the principal 
cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and 
progressive atheromatous disease that cannot be explained by the classical lipid 
parameters used in the daily clinical practice.  
Areas covered: the current review summarizes prevailing knowledge on the role of 
lipids in atheromathosis in CKD patients, including an overview of lipoprotein 
metabolism highlighting the CKD-induced alterations. Moreover, to obtain information 
beyond traditional lipid parameters, new state-of-the-art technologies such as 
lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse 
the potential of new lipoprotein subclasses as therapeutic targets in CKD. 
Expert opinion: the CKD-induced lipid profile has specific features distinct from the 
general population. Besides quantitative alterations, renal patients have a plethora of 
qualitative lipid alterations that cannot be detected by routine determinations and are 
responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein 
particle number and size, together with new biomarkers obtained by lipidomics will 
personalize the management of these patients. Therefore, nephrologists need to be 
aware of new insights into lipoprotein metabolism to improve cardiovascular risk 
assessment. 
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1. Introduction 
Chronic kidney disease (CKD) is a complex clinical entity in which the function and 
structure of the kidneys are impaired. CKD is a global health issue with an increasing 
incidence and prevalence, mostly due to population aging and the rising frequency of 
diabetes, hypertension, and obesity. Progression of CKD towards end-stage renal 
disease (ESRD) represents a huge economic burden to healthcare systems since it 
increases the need for expensive renal replacement therapies [1, 2].  
Over the past years, a large body of evidence strongly supports that CKD is 
accompanied by a significantly higher cardiovascular mortality, being cardiovascular 
disease (CVD) the primary cause of morbidity and premature mortality in renal patients. 
CKD patients show a higher incidence of coronary artery disease, myocardial 
infarction, congestive heart failure, cerebrovascular disease, peripheral arterial 
disease, and sudden cardiac death [3, 4]. In general terms, cardiovascular mortality 
rises as filtration rate declines. It is much higher in CKD stages 4-5 than in the general 
population, and markedly higher in ESKD as compared to earlier CKD stages [5]. 
Cardiovascular risk factors present in CKD can be classified as traditional or specific 
[6]. On the one hand, traditional risk factors that predict ischemic outcomes in the 
general population frequently coexist in renal patients. Interestingly, some of them do 
not show the same epidemiological behavior as in the general population, such as 
hypercholesterolemia, hypertension, and obesity [7]. On the other hand, specific risk 
factors that correlate with filtration rate reduction (such as anemia, inflammation and 
malnutrition) are also responsible for part of the cardiovascular risk excess in CKD 
patients [8]. One of the specific risk factors in which nephrologists have extensively 
focused their attention is vascular calcification, a phenomenon related to the very 
frequent alterations in mineral metabolism parameters found in CKD patients. These 
alterations, called chronic kidney disease-mineral and bone disorder (CKD-MBD), play 
a very important role in the physiopathology and progression of CVD in the CKD 
population. In fact, experimental evidence supports the existence of an important 
crosstalk between bone, kidney and the cardiovascular system [9].  
Historically, vascular calcification had masked the relevance of atheromatosis in CKD, 
in part due to its high prevalence and the precocity of this complication. However, in the 
last decade atheromatosis and its clinical implications have gained importance in the 
renal population. The National Observatory of Atherosclerosis in Nephrology 
(NEFRONA) study, led by our group, was the first large longitudinal study describing 
the actual prevalence and associated risk factors of subclinical atheromatosis across 
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different CKD stages [10, 11]. Patients with early CKD already have a higher 
prevalence of atheromatous plaques than those with normal renal function, and this 
prevalence is even higher in more advanced stages of CKD. Interestingly, a group of 
patients had plaques in femoral arteries but not in carotid arteries [12]. This highlights 
the importance of a wider ultrasound examination beyond carotid arteries to properly 
diagnose the disease. The results also show that the adjusted probability of having 
atheromatosis in CKD patients is 20-30% higher compared to matched controls with 
normal renal function [13]. Interestingly, CKD patients exhibit a more progressive and 
prevalent atheromatous disease, despite the fact that they lack the lipid profile 
commonly associated with atheromatosis in the general population [14]. Specific 
factors related to CKD have been identified as associated with atherosclerosis in this 
population [15-19]. However, the residual risk remains extremely high, and further 
research on risk factors affecting CKD-related atherosclerotic disease is urgently 
needed. Indeed a more precise characterization of the lipid profile seems a reasonable 
field for research. 
Notwithstanding the growing scientific literature regarding cardiovascular risk factors, 
little progress has been made in the field of risk evaluation in patients with CKD. Given 
that lipid parameters currently measured in daily clinical practice do not explain the 
excess of atheromatous burden in renal patients, it is of paramount importance that the 
Nephrology community reconsiders the role of traditional lipid measurements to 
calculate cardiovascular risk in these patients. In contrast, nephrologists should 
consider the possibility of incorporating the use of new state-of-the-art technology that 
can provide information beyond traditional lipid parameters. In this review, we provide 
an overview of the normal lipoprotein metabolism, the lipid alterations induced by CKD, 
new approaches for lipoprotein characterization, and a brief description of the 
treatments of dislipemia in CKD, as well as our view on the importance of the new 
parameters of lipid metabolism with potential clinical research value in the renal 
population. 
2. A snapshot of lipoprotein metabolism 
Cholesterol esters and triglycerides are the two most important types of circulating 
lipids [20]. Due to their hydrophobicity, they need to be contained within particles called 
lipoproteins. They transport lipids from sites of absorption and/or synthesis to sites of 
consumption or processing. Based on their density, lipoproteins can be classified as 
chylomicrons, very-low-density lipoproteins (VLDL), intermediate-density lipoproteins 
(IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). They show 
5 
 
significant differences in particle diameter, density, lipid components and apolipoprotein 
composition (figure 1). Lipoproteins have a hydrophobic core that contains cholesterol 
esters and triglycerides and a hydrophilic envelope formed by phospholipids, 
apolipoproteins and free unesterified cholesterol. Apolipoproteins have structural 
functions but also control lipoprotein metabolism through regulation of some enzymatic 
activities and receptor interactions (table 1). 
Chylomicrons are triglyceride-rich lipoproteins (TGRLs) that are involved in absorption 
of exogenous dietary lipids. They are assembled by enterocytes, secreted into 
intestinal lymph and transported to bloodstream. Once in blood circulation, they are 
metabolized within minutes by the endothelium-associated lipoprotein lipase (LPL), 
thereby releasing free fatty acids (FFA), which are absorbed by the liver, muscle, and 
adipose tissues. As a consequence, a smaller, cholesterol-enriched particle, called 
chylomicron remnant is formed, which will be removed from circulation by the liver via 
the LDL receptor-related protein (LRP) [21]. 
VLDLs are TGRLs that transport endogenous triglycerides from the liver to peripheral 
tissues. LPL reduces their triglyceride content releasing FFA, which are absorbed by 
the liver, muscle, and adipose tissues. Therefore, VLDLs become smaller and relatively 
enriched in cholesterol esters forming IDLs. Then, IDLs are either removed from the 
bloodstream by the liver via LDLR or transformed into LDL due to a further LPL and 
Hepatic lipase (HL) mediated hydrolysis. During these consecutive transformations, 
they accumulate cholesterol esters and their triglyceride content declines [22]. 
LDLs transport the major proportion of cholesterol to the liver and peripheral tissues. 
They originate from IDLs that have further reduced their triglyceride content by the LPL 
and HL (as previously described); or from HDL particles that have gained additional 
cholesterol esters in a transfer process mediated by the cholesterol ester transfer 
protein (CETP). The interaction of LDL particles with LDLR promotes their 
internalization, thereby removing them from the bloodstream. After endocytosis, the 
LDL particle is degraded, cholesterol cargo is released, and LDLR is recycled to the 
cell surface. The LDLR recycling can be compromised by the proprotein convertase 
subtilisin/Kexin type 9 (PCSK9), which fosters intracellular lysosomal degradation; 
hence, limiting LDLR abundance on the cell membrane and LDL internalizacion [23]. 
HDLs are the main players in reverse cholesterol transport from peripheral tissues to 
the liver. This process starts with the extraction of cholesterol from peripheral tissues in 
a process known as cholesterol efflux. The extracted free cholesterol is esterified by 
the lecithin-cholesterol acyltransferase (LCAT) protein and stored in the core of the 
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HDL particle. This leads to the transformation of lipid-poor discoid HDL particles to 
spherical cholesterol-rich HDL particles, which then detach and are released into the 
bloodstream. In circulation, CETP transfers part of the cholesterol content of HDLs to 
IDLs and LDLs in exchange for their triglycerides. Finally, HDL particles are absorbed 
by the liver allowing lipid cargo release. After unloading of the lipid content, lipid-poor 
HDLs return to the circulation to repeat the cycle [2]. 
3. A brief overview of CKD-induced dyslipidemia 
CKD patients show a dyslipidemia with distinct features from that of the general 
population. It is characterized by hypertriglyceridemia, varying levels of LDL cholesterol 
(LDL-C), an accumulation of TGRLs and low HDL cholesterol (HDL-C) levels [24]. The 
lipid profile has specific features depending on the CKD stage, proteinuria level, and 
type of renal replacement therapy [25, 26] (table 2). CKD impairs lipid metabolism in 
such a manner that all lipoprotein classes are altered to some extent (figure 2). 
Besides, renal patients have a plethora of qualitative lipid alterations that cannot be 
detected by routine determinations and has a strong impact on the progression of the 
disease. 
TGRLs, such as chylomicrons, VLDL, and their remnants, accumulate in CKD patients 
from the earliest stages of renal dysfunction and show the highest levels in nephrotic 
syndrome and in peritoneal dialysis. This accumulation is the consequence of both a 
high production rate and a low catabolic rate [27]. Therefore, the artery wall is exposed 
to high plasma levels of TGRLs, which promotes atherogenesis. 
IDLs, which are highly atherogenic, also accumulate in CKD patients due to: (i) a 
downregulation of hepatic lipase expression which impairs conversion of IDL into LDL 
[28]; and (ii) a reduced expression of LDLR and LRP in the liver that compromise 
particle removal [29]. 
Non-HDL cholesterol and Remnant cholesterol. The non-HDL cholesterol is 
cholesterol carried by ApoB-containing lipoproteins. Because any particle with a 
diameter below 70 nm can penetrate the artery wall, in situations characterized by an 
increased number of TGRL-derived particles such as CKD, they should be taken into 
account. 
Cholesterol carried by non-HDL and non-LDL particles, is referred to “remnant 
cholesterol”. It includes chylomicrons and VLDL remnants and IDLs. This group of 
particles is important in hypertriglyceridemia states because they accumulate and 
penetrate into the artery wall where they deliver high amounts of cholesterol. In fact, in 
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hypertriglyceridemia states such as CKD, these particles transport more cholesterol 
than LDL particles. This must be taken into account in postprandial states, insulin 
resistance situations and in general, in all patients with an atherogenic dyslipidemia 
profile as CKD subjects.  
LDL-C levels depend on the stage of CKD. Whereas in early stages patients show high 
LDL-C levels, in ESRD and particularly in hemodialysis they show normal or reduced 
concentrations [30]. Usually, renal patients show a reduced LDL particle catabolism 
and a decreased production of LDLs, resulting in nearly normal or reduced amounts. 
However, nephrotic syndrome is commonly associated with elevated LDL-C due to an 
overproduction of these particles. Beyond the quantitative difference, there is a 
significant qualitative modification of LDL particles in CKD. They become more 
atherogenic due to abnormal post-translational modification of their components. The 
oxidative environment associated with uremia favors several levels of oxidation, 
glycosylation and carbamylation that boost atherosclerosis [31].  
Lipoprotein(a), also known as Lp(a), is an LDL-like molecule that contains an 
apolipoprotein(a) molecule attached to an LDL particle. Although many aspects of its 
metabolism remain elusive and its specific function remains unveiled, Lp(a) has 
demonstrated a pro-atherogenic effect [32]. In CKD, Lp(a) levels rises as filtration rate 
declines [33]. It has been correlated with coronary heart disease and cardiovascular 
mortality in hemodialysis patients [34]. An in vivo turnover study demonstrated a 
diminished clearance of Lp(a) in hemodialysis patients without a significant difference 
in the production rate compared to control patients [35].  
HDL-C levels are usually reduced in renal patients. CKD compromises HDL 
metabolism in several manners. First, HDL maturation is limited due to a reduction of 
its apolipoproteins and LCAT levels, especially in dialysis patients [36]. Second, HDL 
particles also undergo abnormal post-translational modifications [37]. These alterations 
impair cholesterol efflux [38], anti-oxidative and anti-apoptotic functions, 
vasorelaxation, and inhibition of adhesion molecules expression [39]. Therefore, these 
modifications explain the diminished cardiovascular protective effect of HDLs observed 
in the CKD population. 
Qualitative changes are very common in CKD. In renal patients, the antioxidant 
defenses are lowered leading to an enhanced oxidative stress [40]. This phenomenon 
appears almost at the beginning of CKD and increases as the filtration rate declines. 
Lipids and proteins are especially vulnerable to oxidation and this alteration alters their 
biological function. There are several oxidative modifications described in CKD. On the 
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one hand, proteins can be carbonyled. This modification creates advanced glycation 
end products (AGEs) and advanced lipoxidation end products (ALEs) that accumulate 
in CKD. AGEs and ALEs have a strong impact on atherosclerosis since they favor LDL 
oxidation and display several pro-inflammatory effects, respectively [41, 42]. On the 
other hand, proteins can be carbamyled. Protein carbamylation is associated with CVD, 
mortality in CKD, affects lipoproteins and promotes atherosclerotic complications. 
Finally, cholesterol, phospholipids, fatty acids and lipoproteins are prone to oxidation. 
These modified molecules are very reactive and have a negative impact on body 
homeostasis [30]. 
4. New insights into lipoprotein characterization 
As previously stated, CKD is associated with systemic inflammation, dyslipidemia, 
oxidative stress, accelerated atheromatosis and premature deaths from CVD [43]. 
Several aspects of this disease pointed towards the limited contribution of traditional 
lipid parameters. First, High LDL-C levels are associated with cardiovascular risk in the 
general population as well as in the CKD population. However, despite that most CKD 
patients show nearly normal or low LDL-C, data from the NEFRONA study indicate that 
the prevalence of atheromatosis was 68.7% and progressed in more than one half of 
patients with CKD after 24 months [13]. The multivariate logistic analysis revealed that, 
a part from triglyceride levels in CKD stage 3, there is not a clear association of 
traditional lipid parameters with the presence of atheromatous plaque [13]. Second, 
there is a considerable residual risk even at low levels of LDL-C in this population, 
particularly in ESRD patients. In fact, statins show a reduced benefit as CKD advances 
[44]. Altogether, these data indicate that the traditional lipid parameters are not at the 
forefront and therefore, a different approach is required. Modern detail analyses such 
as lipoprotein particle profiling, metabolomics and lipidomics may improve vascular risk 
assessment in this population. 
4.1. Particle number 
 Besides LDL-C and HDL-C measurements that reflect the cholesterol mass within 
LDLs or HDLs, respectively, the actual lipoprotein particle number can be determined. 
In the past few years, although it is not a parameter that is determined in the daily 
clinical practice, particle number has demonstrated to be clinically relevant. 
Cardiovascular risk has been shown to be more closely related to LDL particle number 
(LDL-P) than LDL-C, especially when these parameters are discordant [45]. Indeed, 
two individuals having the same amount of LDL-C could have different cardiovascular 
risk if their LDL-P levels are different. Since the correlation of LDL-P with 
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cardiovascular risk is more accurate than LDL-C, these two individuals have different 
probability to develop cardiovascular events, having more risk the one that has higher 
LDL-P levels. Multiple studies, such as VA-HIT, MESA, and JUPITER, also concluded 
that an elevated HDL particle number (HDL-P) predicted a reduced risk of coronary 
heart disease [46]. Therefore, particle number seems to be a stronger predictor of 
cardiovascular events than the classical routine lipid parameters. 
Another approach to assess particle number is to quantify apolipoproteins. This is 
based on the fact that all potentially atherogenic lipoprotein particles (VLDL, IDL, LDL, 
and Lp(a)) contain a single apolipoprotein B (ApoB) molecule whereas anti-atherogenic 
HDL particles can contain several ApoA1 molecules. Therefore, it has been proposed 
that measuring apolipoproteins could improve cardiovascular risk assessment [47]. A 
recent study showed that ESKD patients show decreased levels of ApoA1 and ApoB 
compared to early stages [48]. 
4.2. Lipoprotein size 
Nowadays, there are several techniques available to perform a deeper characterization 
that allows the separation of lipoproteins in different subfractions according to their 
size. Several studies have shown that small dense LDL particles are more pro-
atherogenic than large LDL particles [49] because (i) small LDL particles have more 
ability to penetrate the endothelial cell barrier and accumulate beneath the intima; (ii) 
they are more easily oxidized; and, (iii) they remain in circulation for a longer time. It 
has been demonstrated an accumulation of small dense LDL particles in CKD, with a 
negative prognosis on cardiovascular events [50, 51]. Regarding HDLs, high levels of 
large HDL particles correlate with less probability to develop atherosclerosis, while 
small HDL particles behave as a pro-atherogenic subclass [52]. Low levels of large 
HDL particles and high levels of small HDL particles correlate with a higher risk of 
incident cardiovascular events[53]. Curiously, two recent publications in CKD 
population showed unexpected results. First, the levels of small  pro-atherogenic HDL 
particles decrease with CKD severity [48]. Second, haemodialysis patients have more 
of large HDL species, while small HDL species are more frequent in healthy people 
[54]. The clinical implications of such findings require further investigations. 
Despite the extensively proven beneficial effect of statins reducing LDL-C levels and 
cardiovascular events, statins do not decrease the proportion of pro-atherogenic small 
dense LDL particles and do not reduce Lp(a) levels. Unfortunately, for long time, the 
only available therapeutic option to reduce both particles was plasmapheresis. 
Surprisingly, PCSK9 inhibitors, a part from having a potent effect on reducing LDL-C 
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and cardiovascular events [55], they also decrease plasma Lp(a) levels [56] and have a 
strong impact on lipoprotein subfractions. They significantly reduce mean 
concentrations of total LDL-P, large and small LDL-P and total VLDL particles; and, 
unexpectedly, they increase HDL-P, being greater in large versus medium or small 
particles [57]. Therefore, although the clinical implications of these observations in the 
CKD population remain elusive, PCSK9 inhibitors could provide an extra benefit to 
these patients. 
4.3. Metabolomics & lipidomics 
 Unfortunately, none of the traditional lipid parameters is sensitive and specific enough 
by itself to evaluate cardiovascular risk in CKD. Based on that, the specific 
apolipoprotein and lipid composition are extremely valuable, since they can be used as 
novel biomarkers. New biomarker discovery requires advanced techniques such as 
metabolomics and lipidomics. Metabolomics is the systematic analysis of metabolites 
such as carbohydrates, amino acids, organic acids, nucleotides, lipids, and dipeptides 
in a given sample. Lipidomics, which is an essential part of metabolomics, aims to 
characterize the lipid species in a given sample [58].  
Metabolomics has been used to evaluate potential biomarkers as well as therapeutic 
targets in many diseases such as cancer, metabolic diseases and neuropsychiatric 
diseases [59]. It provides information about the underlying cause, progression rate, and 
treatment response. Several excellent reviews reported metabolomic approaches 
applied to renal diseases [60, 61]. Metabolomics is crucial to study uremic toxins, acute 
kidney injury, diabetic nephropathy, polycystic kidney disease, kidney cancer, and CKD 
[62]. Moreover, it is extremely valuable to evaluate nephrotoxicity of therapeutic drugs 
and environmental pollutants given its high sensitivity [63].  
There are two main approaches. Non-targeted and targeted lipidomics. Non-targeted 
lipidomics aims to identify without bias as many lipids as possible. It is used in 
hypothesis-generating studies such as biomarker discovery [64]. On the contrary, 
targeted lipidomics aims to quantify a selected group of lipids exploring specific 
metabolic pathways or validating biomarkers previously identified using a non-targeted 
lipidomic profiling (discovery experiment) [65]. Since both approaches have pros and 
cons, most researchers choose to combine them. First, a non-targeted approach is 
conducted to identify as many candidates as possible in a discovery cohort. Then, 
targeted methods confirm previously identified compounds in a validation cohort to 
obtain more robust data [66]. Metabolomics and lipidomics data analyses require 
sophisticated statistical methods in order to show results in a meaningful way [67].  
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CKD has a strong effect on general metabolism. Over the last decade, hundreds of 
publications reported that CKD affects amino acids and their metabolites, nitric oxide, 
polyamines, urea cycle metabolites, uric acid, acylcarnitines, and lipids [68, 69]. The 
discovery of new biomarkers will generate a metabolomic signature that may improve 
early diagnosis of CKD, provide modern tools for monitoring progression of the disease 
and treatment response [70]. Metabolomics allows detection of dynamic changes in 
lipid metabolism before and after the onset of detectable changes in renal function or 
histology [71]. In that sense, the combination of some biomarkers, such as ricinoleic 
acid, stearic acid, cytosine, lysophosphatidic acid (LPA)(16:0), LPA(18:2), 3-
methylhistidine, and argininic acid allow the discrimination of patients with CKD from 
healthy subjects regardless of the underlying cause [72]. CKD patients accumulate 
total fatty acids, glycerolipids and glycerophospholipids that directly correlate with 
increased serum triglyceride levels and inversely correlate with estimated glomerular 
filtration rate (eGFR) [73]. In addition, detection of some of these lipid compounds such 
as monoacylglycerols and diacylglycerols can improve prediction of progression of 
CKD beyond eGFR and urine protein-creatinine ratio [74]. CKD also provokes the 
activation of inflammatory/oxidative pathways and suppression of antioxidant pathways 
that generate a specific metabolic fingerprint [75, 76].  
Finally, in order to unveil currently unknown questions regarding CKD, an integrative 
system biology approach is required to combine all the information gathered from 
traditional lipid parameters, lipoprotein profiling and omic technologies [77]. 
5. Therapeutic approach to CKD displipemia 
The management of dislipemia in renal patients has recently been reviewed [26, 78]. 
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise a 
therapeutic lifestyle change in adults with CKD. These changes include dietary 
modification, weight reduction, increased physical activity, reducing alcohol intake, and 
treatment of hyperglycemia if present. In addition, patients with high fasting TG serum 
levels (>500 mg/dL) should adopt a low-fat diet (<15% total calories), reduce 
monosaccharide and disaccharide intake, as well as the total amount of dietary 
carbohydrates, and use fish oil to replace some long-chain TG [79]. 
It is recommended to evaluate lipid profile (TC, LDL-C, HDL-C, and TG) in adults with 
newly identified CKD. However, follow-up measurement of lipid levels is not required 
[79]. 
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Some epidemiological studies revealed controversial results regarding lipid-lowering 
therapy and reduction of cardiovascular mortality in CKD patients. The SHARP study 
demonstrated that simvastatin and ezetimibe combination therapy was associated with 
lower risk of major atherosclerotic events compared to placebo in patients with CKD 
stage 3A-5 [80]. On the other hand, the 4D [81] and AURORA [82] trials conducted in 
patients treated with dialysis showed no positive effect on the primary composite 
endpoint of cardiovascular disease.  
KDIGO guidelines recommend treatment with a statin or statin/ezetimibe combination 
in (i) adults aged ≥ 50 years with eGFR <60 mL/min/1.73 m2 who are not in dialysis or 
transplanted (GFR categories: G3a-G5); (ii) adults aged ≥ 50 years with eGFR >60 
mL/min/1.73 m2 (GFR categories: G1-G2); (iiI) adults aged 18-49 years with CKD who 
are not in dialysis or transplanted, in the case of known coronary disease (myocardial 
infarction (MI) or coronary revascularization), diabetes, prior ischemic stroke or an 
estimated 10-year incidence of coronary death or non-fatal MI >10%; and, (iv) adult 
kidney transplant recipients; On the contrary,  in adults with dialysis-dependent CKD, 
statins or statin/ezetimibe combination is not recommended to be initiated. However, 
patients are recommended to continue their lipid-lowering therapy although dialysis 
treatment is initiated [79]. 
Finally, although hypertriglyceridemia is frequently present in CKD patients, fibric acid 
derivates are only used in cases of markedly elevated fasting TG (>1000 mg/dL) and 
should not be combined with statins because of potential toxicity [79]. 
6. Conclusions 
The primary cause of morbidity and premature mortality in renal patients is 
cardiovascular disease. These patients show a higher prevalence of atheromatous 
disease from early stages, being even higher in advanced CKD stages. Surprisingly, 
although this population do not show the lipid profile commonly associated with 
atheromatosis in the general population, their atheromatous disease is more 
progressive.  
The CKD-induced dyslipidemia shows hypertriglyceridemia, varying levels of LDL-C, an 
accumulation of TGRLs and low HDL-C. These parameters are modified depending on 
the stage of the disease, proteinuria levels, and the renal replacement therapy.  CKD 
compromises lipid metabolism affecting all lipoprotein classes, creating a specific lipid 
profile in these patients.  
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Besides the classical lipid alterations, recent approaches have revealed that there is a 
huge plethora of qualitative changes in lipoproteins. The combination of state-of-the-art 
techniques in metabolomics and lipidomics with advanced lipid tests such as 
lipoprotein subfraction profiling present an opportunity in order to progress towards 
precision medicine. These modern approaches will allow a better understanding of the 
CKD-induced dyslipidemia, they may also improve cardiovascular risk assessment, 
and it will eventually generate new therapeutic tools for cardiovascular disease 
prevention in patients with renal dysfunction. Therefore, translational research in this 
field must become a priority for nephrologists.  
7. Expert Opinion 
In the past few years, it has become evident that the information gathered from 
traditional lipid parameters shows important limitations in CKD patients because (i) they 
show a high prevalence of atheromatosis despite low LDL-C levels; (ii) there is not a 
clear association of other traditional lipid parameters with the presence of 
atheromatous plaque; and (iii) statins show a reduced benefit in advanced CKD stages, 
compared to early stages. Therefore, there is a clear need to find the real link between 
CKD-related lipid metabolism alterations and the excess of atheromatosis and 
cardiovascular disease in renal patients. 
Several publications have highlighted the importance of a more detailed lipoprotein 
analysis. The importance of particle number and size has been extensively proven in 
the general population. In fact, the scientific community has accepted that lipoprotein 
subfraction profiling improves cardiovascular risk assessment compared to traditional 
lipid parameters. Unfortunately for nephrologists, there are very few studies of 
advanced lipoprotein profiling conducted in CKD patients and the clinical implication of 
such findings remain elusive. Therefore, clinical research in this field is urgently 
needed. 
The potential of lipidology research in renal patients is unlimited since there are many 
questions to be answered. The ultimate goal in this field is to understand the impact of 
CKD on lipid metabolism and uncover the modifications responsible for the accelerated 
atheromatosis. Understanding the specific lipid alterations could enable the 
development of new therapeutic targets.  
To achieve those goals clinicians need to be aware of new state-of-the-art techniques 
that will bring light to this field. One of the biggest challenges in the near future is the 
application of advanced lipoprotein test in the daily clinical practice. To our knowledge 
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the future of lipidology will evolve together with the appearance of new techniques 
more accessible to clinicians that will allow a better characterization of lipid alterations.  
 
8. Article highlights 
 
1. CKD patients show a high cardiovascular mortality, being cardiovascular 
disease the primary cause of morbidity and premature mortality in renal 
patients. 
2. CKD patients show a higher prevalence and a more progressive atheromatous 
disease that cannot be explained with the information gathered from the 
traditional lipid parameters. 
3. The CKD-induced lipid profile is characterized by hypertriglyceridemia, varying 
levels of LDL cholesterol, and accumulation of TGRL and low HDL cholesterol 
levels.  
4. Besides quantitative changes, there are many qualitative changes such as 
lipoprotein carbonylation, carbamylation and oxidation which are responsible 
from the excess of cardiovascular risk in this population. 
5. New approaches such as lipoprotein profiling, metabolomics and lipidomics 
may improve cardiovascular risk assessment and personalize the treatment of 
these patients. 
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Figure 1. Plasma lipoproteins.  
Major lipoproteins classes according to their density and size distribution (a). Their 
composition is shown in (b). Note that unlike HDL particles, chylomicrons are the 
biggest particles and show the lowest density. Abbreviations: HDL: high-density 
lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density lipoprotein; VLDL: 
very-low-density lipoprotein.  
Figure 2. Lipoprotein pathways and main modifications induced by CKD.  
CKD patients show an accumulation of VLDL, chylomicrons and their remnants due to 
a higher production and a lower catabolic rate. The reduced LPL activity reduces FFA 
release. IDLs also accumulate as a consequence of a downregulation of HL activity 
and a reduced expression of LDLR. The production and elimination of LDL particles are 
reduced and they suffer from abnormal modifications that increase their pro-
atherogenic effect.  HDL maturation is impaired in renal patients due to a reduced HDL 
precursor production, a reduced cholesterol efflux, and a reduced production and 
activity of LCAT. This leads to a reduced amount of spherical HDL particles and an 
increased amount of discoid HDL particles. Finally, the increased CETP levels reduce 
the amount of cholesterol present in HDL particles and increase their triglyceride 
content.  
Abbreviations: CE: cholesterol ester; CETP: cholesterol ester transfer protein; CM: 
chylomicron; CMr: chylomicron remnant FFA: free fatty acids; HDL: high-density 
lipoprotein; HL: hepatic lipase; IDL: intermediate-density lipoprotein; LCAT: lecithin 
cholesterol acyltransferase; LDL: low-density lipoprotein; LDLR: LDL receptor; LPL: 
lipoprotein lipase; TG: triglyceride; VLDL: very-low-density lipoprotein. Figure adapted 
from Kwan et al. [2]. 
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Table 1. Main types of plasma apolipoproteins 
 
 
Abbreviations: CETP: cholesterol ester transfer protein; HDL: high-density lipoprotein; 
IDL: intermediate-density lipoprotein; LCAT: lecithin cholesterol acyltransferase; LDL: 
low-density lipoprotein; LDLR: LDL receptor; Lp(a): lipoprotein(a); LPL: lipoprotein 
lipase; LRP: LDL receptor related protein; VLDL: very-low-density lipoprotein. 
Apolipoprotein Structural Role Physiologic function 
ApoA-I chylomicrons, HDL LCAT activator 
Apo A-II chylomicrons, HDL LPL regulator, LCAT and CETP cofactors 
ApoA-IV chylomicrons, HDL LCAT activator 
ApoA-V chylomicrons, VLDL, HDL LPL activator, chylomicron assembly 
ApoB-48 Chylomicrons and remnant Structural component of chylomicrons 
ApoB-100 VLDL, IDL, LDL, Lp(a) LDLR ligand 
Apo C-I chylomicrons, VLDL, IDL, HDL LCAT activator 
ApoC-II chylomicrons, VLDL, IDL, HDL LPL activator 
ApoC-III chylomicrons, VLDL, IDL, HDL LPL inhibitor, VLDL assembly 
ApoD 
 
Transport of small lipophilic molecules 
ApoE chylomicrons, VLDL, IDL, HDL LDLR ligand for chylomicron remnants; LRP ligand 
ApoM 
 
Transport of small lipophilic molecules 
Apo(a) Lp(a) Unknown 
17 
 
 
Table 2. Traditional lipid parameter changes in CKD 
 
Parameter CKD 1-5 Nephrotic syndrome Haemodialysis Peritoneal Dialysis 
Total cholesterol  ↑ ↑ ↔↓ ↑ 
LDL cholesterol  ↑ ↑ ↔↓ ↑ 
HDL cholesterol ↓ ↓ ↓ ↓ 
Non-HDL cholesterol  ↑ ↑ ↔↓ ↑ 
Triglycerides  ↑ ↑ ↑ ↑ 
Lp(a)  ↑ ↑ ↑ ↑ ↑ 
 
Plasma levels compared to healthy controls. Explanation of arrows: ↔: normal; ↑: increased; ↑ ↑: markedly increased; : increasing. Non-HDL 
cholesterol includes cholesterol in LDL, VLDL, IDL, chylomicrons and its remnants. Adapted from Kwan C.H et al. [2]. Abbreviations: HDL: high-
density lipoprotein; LDL: low-density lipoprotein; Lp(a): lipoprotein(a)
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Papers of special note have been highlighted as either of interest (*) or of considerable 
interest (**) to readers. 
 
30 ** A comprehensive review of lipid modifications and their implications in CKD. 
 
32 ** A metaanalysis that highlights the role of lipoprotein (a) as a risk factor for ischemic heart 
disease. 
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44** A metaanalysis that shows the effect of statins on all-cause of mortality only in CKd 
patients not in dialysis. 
 
48** Publication that reveals HDL subfractions and their oxidized status in CKD patients 
 
51** Publication that describes the implication of small dense LDL particles in cardiovascular 
events in CKD patients. 
 
55** First clinical trial that demonstrates the effect of PCSK9 inhibitors in reducing LDL 
cholesterol and cardiovascular events. 
  


